Abstract 1036P
Background
PM1003 is a VHH-based anti-PD-L1 x 4-1BB bispecific antibody that exhibits PD-L1 expression-dependent 4-1BB agonism, with excellent anti-tumor activity and safety in preclinical studies.
Methods
The safety and tolerability of PM1003 in patients (pts) with advanced solid tumors were assessed during dose escalation, and pts with advanced solid tumors positive for PD-L1 expression have been enrolled for assessing anti-tumor activity during dose expansion.
Results
At the data cut-off up to Apr. 19, 2023, 23 pts had been enrolled, with 19 pts for dose escalation (3 pts for each of the 0.02, 0.1, 1, 3, 10 mg/kg dose levels and 4 pts for the 6 mg/kg dose level). All pts had prior 1-6 lines of systemic treatment. Dose-limiting toxicity (DLT) was assessed over 21 days after the first dose followed by dosing Q2W. 4 pts were enrolled for dose expansion (2 pts in 1 mg/kg, 1 patient in each of the 3 and 6 mg/kg dose levels, Q2W). No DLTs were observed during dose escalation. Treatment-related adverse events (TRAEs) occurred in 22 pts (95.7%). The most common TRAEs in pts included anemia (39.1%, Grade≥3 0%), aspartic acid aminotransferase increased (30.4%, Grade≥3 4.3%), white blood cell count decreased (30.4%, Grade≥3 8.7%) and platelet count decreased (30.4%, Grade≥3 0%). For the 1 - 10 mg/kg cohorts, T1/2 was 6.3 - 15.3 days after the first dose. PD-L1 target occupancy approach to saturation at 7 days after the first dose and maintained stable. 18 pts were evaluable for efficacy. The objective response rate was 5.6% and the disease control rate was 44.4%. Preliminary antitumor activity was observed in one PD-L1 positive gastric cancer patient (1 mg/kg, Q2W; TPS=5%, CPS=30) who was heavily treated with chemotherapy, anti-PD-1 and anti-HER2-ADC after surgery. 87.8% of tumor shrinkage was achieved in the target lesion at the first efficacy evaluation (7 weeks) after PM1003 treatment. Partial Response was confirmed at subsequent visits.
Conclusions
PM1003 was well-tolerated at doses up to 10 mg/kg and preliminary antitumor efficacy was observed in a patient with prior anti-PD-1 treatment. Expansion cohorts to evaluate efficacy and further safety in PD-L1-positive pts are ongoing.
Clinical trial identification
ChiCTR2100052887.
Editorial acknowledgement
Legal entity responsible for the study
Biotheus Inc.
Funding
Biotheus Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19
1047P - AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Presenter: Ben Tran
Session: Poster session 19